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Multiple myeloma (MM) is a plasma cell malignancy
with impaired bone formation. In myeloma, RANKL
expression is markedly increased while its decoy receptor,
osteoprotegerin (OPG), is decreased (1). The Wnt signal-
ing inhibitor DKK1 expression is significantly increased
and correlates with the extent of bone disease (2, 3). The
ubiquitin–proteasome pathway, an essential cellular deg-
radative system in myeloma cells, can also regulate bone
formation via effects on osteoblast differentiation (4, 5).
Bortezomib, the first proteasome inhibitor, has been
shown to have inhibitory effect on myeloma SCID-hu
model in vivo. Primary human myeloma cells are grown
in a human fetal bone, engrafted in the flank of SCID
mice. In this model, the use of bortezomib (0.5 mg ⁄kg
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twice a week) was associated with disease control and
increase in bone mineral density (BMD) (20 ± 14%),
while myeloma growth induced a decrease in BMD
(13 ± 12%) and progressive tumor in untreated animals.
Exposure of non-myeloma-bearing control mice to
bortezomib also resulted in a significant increase in
BMD (6). While osteoprogenitor differentiation is not
affected by immunomodulatory analogues (lenalidomide,
CC-4047, CC-6032), both bortezomib and immunomodu-
latory compounds retain inhibitory effect on osteoclast
differentiation (7, 8). Retrospective analysis of the bone
alkaline phosphatase (ALP) variation during treatment
of myeloma patients with bortezomib has indicated a
close correlation between myeloma response and drug
activity (9). An analysis of the APEX data showed that a
25% increase in ALP after 6 wks’ treatment was the best
predictor of myeloma response and was associated with
time to progression (10).
The phase 3 Vista trial compared the use of melphalan
and prednisone with or without bortezomib in previously
untreated patients with MM who were ineligible for a
high-dose therapy. Six hundred and eighty-two patients
were randomly assigned to receive nine 6-week cycles of
melphalan and prednisone either alone or with bortezo-
mib (11). A retrospective analysis showed that rates of
bisphosphonates use and bone disease events were signifi-
cantly lower in patients enrolled in the VMP arm com-
pared with the MP control arm (12).
Carfilzomib is a novel inhibitor that binds selectively
and irreversibly to the proteasome resulting in greater
and more sustained inhibition compared with bortezo-
mib, and in vitro studies have shown to be able to over-
come bortezomib resistance (13). Carfilzomib selectively
inhibits the N-terminal threonine protease activity of the
proteasome with minimal cross-reactivity with serine and
other proteases. This analysis is the first to focus on the
variations of ALP and myeloma response in carfilzomib-
treated patients with myeloma.
Material and methods
Retrospective analysis of the relationship between serum
ALP and tumor response was performed on patients
with relapsed or refractory myeloma.
Analysis of serum ALP variation was completed in
patients with myeloma enrolled on two phase 2 studies
(PX-171-003 and PX- 171-004) evaluating the safety and
efficacy of single-agent carfilzomib dosed at 20 mg ⁄m2.
We analyzed data from 38 patients in the PX-171-003-A0
study, a relapsed and refractory myeloma trial for
patients who have received ‡3 prior therapies including
bortezomib and an immunomodulatory drug (IMiD),
along with 29 patients in PX-171-004, a relapsed or
refractory myeloma trial that included bortezomib-naive
patients. All patients received 20 mg ⁄m2 of carfilzomib
on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle and
remained on study until progression, intolerable adverse
events, or withdrawal of consents.
Serum ALP measurements were taken prior to the first
dose of carfilzomib (baseline) and periodically during the
trial. Change in ALP levels from baseline to Cycle 2 Day
1 was measured in a group of 117 patients but only 67
patients with ALP data were evaluable for response.
ALP data were aligned with clinical response data and
(as per international myeloma working group (IMWG)
response criteria) with ALP variations associated with
response groups. All patients enrolled in this study have
signed informed consent approved by the IRB.
Results
Sixty-seven patients were included in this analysis. The
median age was 63 yrs with a median time since diagno-
sis of 4.6 yrs, 52% were men, 84% had relapsed after
Autologous stem cell transplantations, 82% were previ-
ously exposed to bortezomib, and 92% were previously
exposed to an IMiD (Table 1). In PX-171-003, the over-
all response rate (ORR) (‡PR) was 18% and the clinical
Table 1 Patients characteristics
Characteristic
Number of (%) of subjects
003-A0
004
TotalBortezomib treated Bortezomib naive
(N = 38) (N = 29) (N = 51) (N = 117)
Median age (years) 64 63 64 64
Median years since diagnosis 5.9 3.6 3.5 4.3
Gender: male 19 (51.4) 14 (48.3) 28 (54.9) 61 (52.1)
Mean number of prior therapies 6.1 2.9 2.0 3.5
Received bortezomib 37 (100.0) 29 (100.0) 0 (0.0) 66 (54.5)
Received IMiD 37 (100.0) 22 (75.9) 47 (92.2) 106 (90.6)
Received transplant 30 (81.1) 25 (86.2) 41 (80.4) 96 (82.1)
Refractory to most recent therapy 37 (100) 9 (31) 20 (39) 66 (56)
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benefit response (CBR; ‡MR) was 26%, while in PX-
171-004, the ORR was 35.5% overall and 57% in bort-
ezomib-naive patients. Average ALP change from base-
line appeared to be associated with responses. Figure 1
shows ALP variation during treatment in patients
according to clinical response.
ALP increment from baseline, which was most evident
during the second cycle of treatment, was statistically
different in patients who achieved ‡ very good partial
remission (VGPR) compared with all others on Days 1
(P = 0.0049) and 8 (P = 0.006) of Cycle 2. In all
patients achieving a VGPR or better, ALP increased
more than 15 units per liter at Cycle 2 Day 1 over base-
line. An ALP increase over the same period of time was
seen in 26%, 13% and 11% of patients achieving PR,
MR, and SD, respectively.
None of the patients with progressive disease exhibited
a similar increase. Our study indicates that response first
assessed on Day 15 of Cycle 1 parallels the ALP eleva-
tion that returned to baseline levels at the end of Cycle
3. Twenty-nine percent (11 ⁄ 38) of subjects achieving at
least a PR had an increase in ALP of >15 U ⁄L from
baseline, while only 7.6% (6 ⁄ 79) of subjects failing to
achieve at least a PR showed a similar increase. Of the
17 patients that had increases of >15 U ⁄L, 11 patients
(65%) responded (>PR) to carfilzomib treatment. An
increase in serum ALP levels on Cycle 2 Day 1 from
baseline is associated with best response.
Discussion
Several in vivo studies have shown that proteasome inhi-
bition is associated with an increase in bone formation.
Pennisi et al. (6) reported a significant (P < 0.04)
increase in BMD in SCID-rab mice engrafted with MM
cells treated with bortezomib; increases in bone volume,
trabecular thickness, and bone formation were also
observed in bortezomib-treated mice, both in myeloma-
tous and non-myelomatous bones. Similarly, a decrease
in osteolytic lesions and increases in trabecular number
and bone volume have been reported following bortezo-
mib treatment of 5T2MM mice (14).
In a murine model of MM, bortezomib-treated mice
showed a 400% increase in osteoblast numbers compared
with vehicle mice. Furthermore, the bortezomib-treated
mice had around 50% more osteoblasts than tumor-
naive mice, suggesting a more direct effect of bortezomib
on osteoblasts than was seen on osteoclasts in the same
study (14).
This is supported by a previous in vitro study that
demonstrated a direct effect of bortezomib in enhancing
differentiation of fetal human MSCs into osteoblasts (6).
A study by De Matteo et al. (15) showed that osterix,
a key transcription factor required for osteoblast differ-
entiation, is down-regulated in MM but can be up-regu-
lated by bortezomib.
In a prospective phase 2 study, bortezomib was associ-
ated with a statistically significant increase from baseline
in bone volume ⁄ total volume (as assessed via compara-
tive histomorphometric microCT analysis) in six of seven
patients with relapsed ⁄ refractory MM. This study has
also indicated that response to bortezomib was associ-
ated with changes in serum parathyroid hormone (PTH)
concentrations (16).
This retrospective analysis on a subset of patients in
these ongoing phase 2 studies of single-agent carfilzomib
in relapsed or refractory MM has shown for the first time
that elevation in serum ALP during carfilzomib is associ-
ated with best tumor responses. Sixty-five percent (11 ⁄ 17)
of subjects with an increase in ALP of >15 U ⁄L above
baseline achieved a PR or better. Initial tumor response
paralleled the ALP elevation, with ALP values generally
returning to baseline levels at the end of Cycle 3 even if
the response seems to continue. PTH levels were not
measured in these phase 2 studies of carfilzomib.
Taken with previous publications describing bortezo-
mib treatment, these results suggest that this specific ana-
Figure 1 Average alkaline phosphatase change from baseline –
increase associated with response.
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bolic bone phenomenon could be a class effect of protea-
some inhibitors. Additional phase 2 studies with a higher
dose of carfilzomib (i.e. 27 mg ⁄m2) are ongoing. The
data from this small subset analysis suggest that further
exploration of this relationship between bone-derived
markers and myeloma response is warranted.
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